Drug Profile

Midazolam buccal and oral film - SWIPP AB

Latest Information Update: 20 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SWIPP AB
Class 3-ring heterocyclic compounds; Antiepileptic drugs; Benzodiazepines; Chlorinated hydrocarbons; Fluorobenzenes; Hypnosedatives; Imidazoles; Sleep disorder therapies; Small molecules
Mechanism of Action GABA A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

29 Nov 2022 Clinical trials in Epilepsy in Sweden (Buccal) (SWIPP pipeline, November 2022)
29 Nov 2022 Preclinical trials in Sedation in USA (PO) (SWIPP pipeline, November 2022)
29 Nov 2022 SWIPP AB plans to conduct a pre-IND meeting with the US FDA for midazolam oral film in the fourth quarter of 2022 (SWIPP website, November 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com